HIV Medications Flashcards
HIV Antivirals
Drug Classes
- Fusion inhibitors
- Co-receptor Antagonists
-
Reverse Transcriptase Inhibitors
- Nucleoside analogues (NRTI)
- Nucleotide analogues (NRTI)
- Non-nucleoside (NNRTI)
- Integrase Inhibitor
- Protease Inhibitors
Fusion Inhibitors
Drugs & MOA
Enfuvirtide (Fuzeon/T-20)
Binds gp41 ⇒ ⊗ entry of HIV into host cell
Not yet part of a recommended regimen
Reserved for patients resistant to other drugs
Enfuvirtide (Fuzeon)
Adverse Effects
Subcutaneous injection BID
Side effects are local injection site reaction, increased rate of bacterial pneumonia, and hypersensitivity
Co-Receptor Blockers
Drugs & MOA
Maraviroc (Selzentry)
CCR5 Antagonist
- Maraviroc blocks CCR5 co-receptor ⇒ ⊗ viral entry
- Only effective for CCR5-tropic HIV ⇒ susceptibility tests
- Not yet part of a recommended regimen
- Reserved for pts resistant to other drugs
- ~ 55% of pts who fail two antiviral regimens infected w/ CCR5-tropic virus
Maraviroc (Selzentry)
Adverse Effects
- Cough, fever, rash, URI, MSK symptoms, abdominal pain, and postural dizziness
- Black box warning for hepatoxicity
- Cardiovascular events ⇒ poss. ↑ in MI
- Metabolized by cytochrome p450 ⇒ ∆ by enzyme inducers and inhibitors
Reverse Transcriptase (RT)
DNA Synthesis
Makes dsDNA from viral RNA
Nucleoside Analogues
(NRTI)
Part of the first line therapy for AIDS
- Zidovudine (AZT) ⇒ 1st drug in this class but now not as widely used
- Lamivudine (3TC)
- Emtricitabine (Emtriva)
- Abacavir (ABC)
Nucleoside Reverse Transcriptase Inhibitors (NRTI)
MOA
- 2’3’ dideoxyanalogues phosphorylated to triphosphates by host cellular kinases
- Integrated by RT in growing DNA chain
- Reverse transcriptase more susceptible vs mammalian DNA polymerase
- Causes chain termination of RNA → DNA
Nucleoside Analogues
Class Specific Adverse Effects
-
Mitochondrial toxicity
-
⊗ of mitochondrial DNA polymerase 𝛾
- ⊗ DNA replication
- Impaired synthesis of mitochondrial enzymes
- Abnormal oxidative phosphorylation
- Tissue sensitivity ∝ cellular mitochondrial content
- Rare especially w/ agents selected for current use
- Can lead to lactic acidosis, pancreatitis, peripheral neuropathy, myopathy, cardiomyopathy, hepatic steatosis, and lipid dystrophy
- Lactic acidemia ass. w/ common NRTI side effects
- N/V, headache, abd pain, fatigue, weight loss
-
⊗ of mitochondrial DNA polymerase 𝛾
Zidovudine (AZT)
Adverse Effects
frAnemia and neutropenia
May also be related to mitochondrial toxicity
Abacavir (ABC)
Adverse Effects
-
Causes a hypersensitivity reaction
- Not related to mitochondrial toxicity
- Can be fatal
- Occurs in 6% of the population
- Related to HLA-B*5701 variant
- Fever, rash, nausea, malaise, respiratory sx
Nucleoside Analogues
Pharmacokinetics
All of the NRTI’s are excreted in the kidney
Require dosage adjustment in renal insufficiency
Nucleoside Analogues
Drug Interactions
-
Inhibitors of cytochrome p450 (ex. Cimetidine) ⇒ ↑ level of some drugs in this class including AZT
- Probenecid can also increase the levels
- Inducers of cytochrome p450 (Ex. Rifampin) ⇒ ↓ levels
-
Overlapping toxicity
- Avoid drugs with similar adverse effects
-
Competition for activation
- Drugs should not be activated by the same kinase
Nucleotide Reverse Transcriptase Inhibitor (NRTI)
Drugs & MOA
Tenofovir (Vemlidy, Viread)
-
Same as nucleoside analogue but does not need to be phosphorylated
- Administered as a prodrug - Tenofovir alafenamide
- Causes DNA chain termination of RT
- Used in combo w/ a nucleoside analogue
- Used alone as pre-exposure prophylaxis and for Hep B treatment
Nucleotide Analogues
Adverse Effects
Weakness, headache, diarrhea
No reported mitochondrial toxicity